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Abstract 36	
 37	
Objective 38	
Motivated by recent calls to use electronic health records for research, we reviewed the application 39	
and development of methods for addressing the bias from unmeasured confounding in longitudinal 40	
data. 41	
 42	
Design 43	
Methodological review of existing literature 44	
 45	
Setting 46	
We searched MEDLINE and EMBASE for articles addressing the threat to causal inference from 47	
unmeasured confounding in nonrandomised longitudinal health data through quasi-experimental 48	
analysis. 49	
 50	
Results 51	
Among the 121 studies included for review, 84 used instrumental variable analysis (IVA), of which 52	
36 used lagged or historical instruments. Difference-in-differences (DiD) and fixed effects (FE) 53	
models were found in 29 studies. Five of these combined IVA with DiD or FE to try to mitigate for 54	
time-dependent confounding. Other less frequently used methods included prior event rate ratio 55	
adjustment, regression discontinuity nested within pre-post studies, propensity score calibration, 56	
perturbation analysis and negative control outcomes. 57	
 58	
Conclusions  59	
Well-established econometric methods such as DiD and IVA are commonly used to address 60	
unmeasured confounding in non-randomised, longitudinal studies, but researchers often fail to take 61	
full advantage of available longitudinal information. A range of promising new methods have been 62	
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developed, but further studies are needed to understand their relative performance in different 63	
contexts before they can be recommended for widespread use. 64	
 65	
Keywords: method review, unmeasured confounding, unobserved confounding, longitudinal, 66	
observational data, electronic health records 67	
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	  72	
	
What	is	new?	
What	is	already	known	
 Unmeasured	confounding	is	a	threat	to	the	validity	of	observational	studies	based	on	
data	from	non‐randomised	longitudinal	studies	
Key	findings	
 Longitudinal	information	that	can	be	used	to	mitigate	for	unmeasured	confounding	in	
observational	data	is	not	always	fully	or	properly	utilised	in	health	research.	
 Instrumental	variable	analysis	and	difference‐in‐differences	were	the	most	commonly	
encountered	methods	to	adjust	for	unmeasured	confounding	in	a	review	of	the	health	
literature.	
 There	are	a	range	of	promising	new	methods,	some	of	which	utilise	longitudinal	
information	to	relax	the	assumption	of	time‐invariance	for	unmeasured	confounders,	but	
these	are	yet	to	be	widely	adopted.	
What	is	the	implication?	
 All	available	methods	rely	on	strong	assumptions	and	more	research	is	needed	to	
establish	the	relative	performance	of	different	methods	for	particular	problems	and	
empirical	settings.	
	
	
	 5
1 Introduction 73	
	74	
 75	
In the era of “big data” in medicine, the increasing availability of large, longitudinal patient 76	
databases is creating new opportunities for health researchers.  A particular focus is on electronic 77	
health records (EHR) with routinely collected data collated from multiple care sites, often linked to 78	
external databases (e.g. death certificates). Built up over time, EHRs provide a sequential history of 79	
each patient’s encounter with the healthcare system. Examples of EHRs include The Clinical 80	
Practice Research Datalink (CPRD), The Health Improvement Network (THIN), QResearch and 81	
ResearchOne in the UK, and the Kaiser Permanente Northern California Oracle Research Database 82	
in the US. The value of large medical data recorded for administrative purposes in national 83	
registries is already recognised 1,2, with the provision of funds to expand the adoption of EHRs in 84	
research for patient benefit in the US with the Health Information Technology for Economic and 85	
Clinical Health (HITECH) Act of 2009, and in the UK, with a consortium of funding bodies led by 86	
the Medical Research Council. Another important source of information for health care analysis is 87	
databases of insurance claims, such as Medicare in the US, and in this review we do not 88	
differentiate between EHRs and claims data. 89	
 90	
A strength of EHRs and claims data is that they make it possible to study the comparative 91	
effectiveness of interventions and the associated risk of side-effects in a real-world setting. 92	
Although randomised trials provide the gold standard of evidence, observational studies based on 93	
observational patient databases offer the potential to study more patients from a wider variety of 94	
risk groups with a longer follow-up period at a fraction of the cost. However, in the absence of 95	
randomisation, selection for treatment is often knowingly based on specific characteristics, such as 96	
frailty, disease severity or the risk of an outcome. If the indication for treatment is also related to 97	
prognosis, confounding by indication arises leading to biased estimation of effectiveness.  There is 98	
a large pharmacoepidemiologic literature on this topic and current best practice is to use design-99	
based approaches such as the Active Comparator, New User Design to help mitigate bias where 100	
possible3.However, residual differences between the treatment arms other than the treatment itself 101	
may still confound the intervention effect under study whether or not such an approach is used. If 102	
the confounding variables are both known to the study investigators and measurable, then these 103	
could potentially be adjusted for in prospective non-randomised studies. With retrospectively 104	
recruited subjects, however, the recording of such variables is outside the control of the 105	
investigator.  Analyses of non-randomised studies that fail to account for relevant confounders may 106	
have important negative consequences for health policy and patient safety. 107	
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 108	
Methods described as the quasi-experimental (QE) approach4, can be deployed to account for 109	
confounding by unobservable characteristics. These do not attempt to directly adjust for resulting 110	
bias, but use available information to achieve this indirectly under certain conditions and 111	
assumptions.  The aim of this systematic review is to review current practices in dealing with 112	
unmeasured confounding in individual-level longitudinal health data and to capture methodological 113	
developments in this area. While previous systematic reviews have been conducted to look at use 114	
of propensity score methods for measured confounders 5,6, we are unaware of any systematic 115	
review comparing use of methods for addressing unmeasured confounding in non-randomised, 116	
longitudinal data. We were particularly interested in how an individual’s history could be leveraged 117	
to evaluate the effects of unmeasured confounding and how the extra longitudinal information 118	
could be incorporated to improve adjustment for confounding bias. We intend for this review to 119	
contribute to the development of best practice in addressing unmeasured confounding in 120	
longitudinal data. The results should therefore help inform researchers intending to utilise “big 121	
data” from electronic health records. 122	
	123	
2 Methods 124	
 125	
2.1 Search strategy 126	
 127	
Our search strategy was informed by, but not limited to, known methods for addressing 128	
unmeasured confounding. The search strategy is recorded in Appendix	A. The following electronic 129	
databases were searched: MEDLINE (via OvidSp including In-Process & Other Non-Indexed 130	
Citations) and EMBASE (via OvidSp 1996	to	2015	Week	21). We included all citation dates from 131	
database inception to May 2015. All references were exported into Endnote X7 (Thomson Reuters). 132	
 133	
2.2 Inclusion and exclusion criteria  134	
 135	
The review included any non-randomised comparative studies that sought to adjust for unmeasured 136	
confounding in longitudinal data with repeated observations on identifiable individuals. In the 137	
interests of good practice, eligible papers had to explicitly identify the problem of bias arising from 138	
the selection on unobservable characteristics in the data, rather than routinely apply a QE design 139	
without this justification. For estimates of comparative effectiveness, eligible studies had to have 140	
independent control arms for each treatment of interest. Therefore, single arm studies were 141	
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excluded. Studies based on case-only designs, including the case-crossover design and the self-142	
controlled case-series design, in which confounding is controlled by making comparisons between 143	
exposed and unexposed periods for the same individual were also excluded.  Observational studies 144	
were not excluded based on the exposure under study so studies into the effects of passive 145	
exposures (medical conditions, environmental exposures etc) were included alongside studies of 146	
both the intended and adverse effects of active interventions. We note that good proxies for 147	
unmeasured confounding, or observed variables that sufficiently describe a latent variable such as 148	
frailty, would be preferable to dealing with the bias resulting from unmeasured confounders. If 149	
suitable proxies are identified and recorded, then there are in effect no unobserved confounders and 150	
the proxies could simply be adjusted for in the analysis, obviating the need for methods to adjust 151	
for the unobserved confounders. For this reason, adjustments for proxies of unmeasured 152	
confounders, including high-dimensional propensity scores, did not fall within the scope of this 153	
study. To be consistent with the “big data” theme of EHRs, a minimum sample size of 1000 154	
participants was applied. This also set a minimum condition for the application of Instrumental 155	
Variable (IV) and Regression Discontinuity (RD) designs stipulated in the Quality of Effectiveness 156	
Estimates from Non-randomised Studies (QuEENS) checklist. Finally, we only accepted analyses 157	
of individual level data. We were aware that some studies may use analytical methods, such as 158	
difference-in-differences that aggregate the data at a treatment-group level. We therefore only 159	
included those studies, in which the same patients could be tracked over the time-frame of the 160	
sample. Conversely, some methods, such as instrumental variable analysis, make no explicit 161	
demands for longitudinal data at the patient level. However, we included such studies where the 162	
sample was based on the availability of patient-level longitudinal information, with a history 163	
possibly but not necessarily preceding the time of exposure. We did not discriminate between data 164	
sources, as patient-level data will often arise from medical insurance claims in the US, as opposed 165	
to clinically-purposed databases in other countries. 166	
Only studies written in English were included.  167	
 168	
The following publication types were excluded from the review: 169	
 systematic reviews	of primary studies. 170	
 randomised controlled trials 171	
 cross-sectional data  172	
 preclinical and biological studies 173	
 narrative reviews, editorials, opinions 174	
 175	
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2.3 Study selection 176	
	177	
Studies retrieved from the searches were selected for inclusion through a two-stage process 178	
according to the inclusion/exclusion criteria specified above. First, abstracts and titles returned by 179	
the search strategy were screened for inclusion independently by two researchers. In case of doubt, 180	
the article in question was obtained and a subsequent judgement on relevance was based on the full 181	
article. Disagreements were resolved by discussion, with involvement of a third reviewer when 182	
necessary. Following the initial screening, full texts of identified studies were obtained and 183	
screened firstly by a single reviewer. In case of doubt, a second reviewer decided on the suitability 184	
of a paper. Where multiple publications of the same study were identified, data were extracted and 185	
reported as a single study. 186	
  187	
2.4 Evidence synthesis 188	
 189	
The details of each study’s design and methodology and the key characteristics of the data source 190	
were tabulated and discussed. We present a summary of the methods we found that can mitigate for 191	
confounding, or its synonyms as unmeasured, unobserved, hidden or residual. We note the 192	
historical frequency and context of the application of those methods, to comment on progress in 193	
causal inference and identify directions for future research. 194	
3 Results 195	
 196	
3.1 Included studies 197	
 198	
Our searches returned 734 unique titles and abstracts, with 275 papers retrieved for detailed 199	
consideration Of the 275 studies eligible for a full-text review, 154 were excluded (see flow 200	
diagram: Figure	1).  201	
 202	
A total of 121 studies were identified as performing a QE analysis on non-randomised longitudinal 203	
data on human subjects, identifiable at an individual level, and so included for a full review of the 204	
text (Appendix	B). 205	
 206	
The QE methods identified in the review are summarised inTable	1. The most frequent method was 207	
instrumental variable analysis (IVA) found in 86 of the studies (Figure	2) – a method that uses an 208	
unconfounded proxy for the intervention or exposure. For successful adjustment, the proxy or 209	
instrument should be strongly, causally associated with the exposure or intervention, and the 210	
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instrument should only affect the outcome through the exposure. In addition to IVA, three of these 211	
also applied difference-in-differences (DiD) – a method that typically uses pre-exposure outcomes 212	
to adjust for unmeasured confounding and assumes any trends unrelated to the exposure are the 213	
same in both groups. Seven more studies derived estimates from a combination of both IVA and 214	
DiD, two of which assumed an absence of higher order autocorrelation to use lagged observations 215	
of the treatment variable as an instrument. Beside the 11 studies applying DiD either in conjunction 216	
with or in addition to IVA, we identified a further 21 studies, in which the sole QE method was 217	
recognised as a DiD approach. 218	
 219	
We found five studies applied the prior event rate ratio method, a before-and-after approach that 220	
can be aggregated to the treatment level for survival or rate outcomes and analogous to DiD. In all 221	
five cases the methods were applied to longitudinal, individual patient data. Similarly regression 222	
discontinuity (RD) was used for such data in three of the studies included for review. Another three 223	
focused on propensity score calibration (PSC). One study introduced perturbation testing and 224	
perturbation analysis, while another discussed the use of negative control outcomes.  225	
 226	
3.1.1 Studies excluded at full text 227	
 228	
The principal reason for exclusion in 94 of the studies, according to our eligibility criteria, was the 229	
absence of longitudinally observed, non-randomised outcomes on all individually identifiable 230	
persons, although other characteristics may also have justified their exclusion. No particular 231	
method was associated with the absence of longitudinal data on identifiable individuals with this 232	
studies in this exclusion category comprising 59% DiD and 28% instrumental variable analyses 233	
compared, respectively, to 53% and 32% of all 154 of the rejected studies. Having fewer than 1000 234	
longitudinally observed individuals excluded 23 studies, among which those using instrumental 235	
variable analysis (IVA) numbered 15. Seven were excluded for not employing a QE method for 236	
unmeasured confounding. Five studies presented exploratory analyses without a focused clinical 237	
question; five were either method reviews or commentaries without an application of methods to 238	
data; one study duplicated a dataset already marked for inclusion, while another failed to specify 239	
the instrumental variable used. Of particular note were the 18 studies using the DiD approach that 240	
were excluded because no explicit justification was made for using the method to address 241	
unmeasured confounding, or any of its synonyms. In these studies, justification of the method was 242	
centred more on econometric concerns over time trends, and presented in terms of controlling for 243	
those trends rather than pre-existing differences between the control and exposed group. 244	
 245	
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3.2 Results of the included studies 246	
 247	
So far studies have been categorised according to their identified QE method. However, certain 248	
properties are shared across some of the methods, and can be classified according to how they 249	
reconcile their specific assumptions with the information offered by the structure of big, 250	
longitudinal data that typifies EHRs. In particular, we organised our results around how each 251	
method had incorporated longitudinal information, and the assumptions required. The stable of 252	
before-and-after methods, that includes PERR and DiD, implicitly incorporates longitudinal 253	
information. Thereafter the challenge is how to relax the assumption of time-invariant confounding. 254	
Conversely, IVA is not uniquely applicable to longitudinal data, but we were able to broadly 255	
classify the types of instruments used (Table	2), some of which did utilise longitudinal information. 256	
We found out of the total 121 studies, 77 incorporated some element of longitudinal information 257	
into their analysis. 258	
 259	
3.2.1 Incorporation of external/additional data 260	
 261	
The propensity scores (PS), the predicted probability of exposure or treatment conditioned on 262	
measured confounders,were used in the seminal work on propensity score calibration (PSC) by 263	
Stürmer to calibrate an error-prone PS against a gold-standard PS and hence arrive at an inference 264	
for the level of unmeasured confounding bias 7. The two subsequent PSC papers examined the 265	
tenability of the method’s assumptions, firstly using simulated data to evaluate the conditions 266	
necessary to violate the surrogacy assumption 8. The second primarily used simulated data and 267	
applied the results to registry data to demonstrate a framework for determining size and direction of 268	
bias from one measured and one hidden confounder 9. 269	
 270	
3.2.2 High-dimensional data 271	
 272	
Since PSC collapses multiple, potential confounding variables down to the single dimension of a 273	
propensity score, the three PSC papers can also be considered a means of dealing with high-274	
dimensional data. In addition to these, our review also included a novel data-mining approach that 275	
proposed to exploit the many factors (perturbations) that may be weakly associated with the 276	
unmeasured confounders from a high dimension dataset 10, for which longitudinal data may 277	
mitigate for incorrect adjustment of a collider. Perturbation analysis was successfully demonstrated 278	
on simulated data, although accidental inclusion of a measured confounder required many more 279	
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perturbations to correct the resulting bias. Both the perturbation method and PSC were also 280	
proposed as sensitivity analyses. 281	
 282	
3.2.3 Quasi-experimental adjustment without longitudinal assumptions 283	
 284	
Those studies characterised as using a QE method without any longitudinal dimension were PSC 285	
and PT as described above. We also added to this category 11 examples of Mendelian IVA 11–21 286	
plus 32 other IVAs without historic or lagged instruments 22–53. While time-based instruments may 287	
at first seem longitudinal, these instruments, such as date of therapy, would need to be related to 288	
previous exposures or outcomes to be considered longitudinal. In some cases, survival times or rate 289	
data were used, but such outcomes do not intrinsically imply longitudinal adjustment for 290	
confounding. In spite of these “cross-sectional” approaches, all studies were based on some form of 291	
longitudinal data at the person level, as demanded by our inclusion criteria. Among the 43 non-292	
Mendelian IVA papers in this non-longitudinal category, one study adjusted for non-longitudinal 293	
fixed effects within twins 39. In another three, discussed below, the analysis was supplemented with 294	
DiD 38,47, and with IVA applied to first-differences54. 295	
 296	
One study examined the effect of lagged, cumulative exposure to radiation on lung cancer in 297	
uranium miners and nuclear workers 55. The problem of unmeasured confounding was addressed 298	
using a method developed in earlier work that proposed negative control outcomes and exposures 299	
as a means of both detecting and potentially resolving confounding bias56. Here the choice of death 300	
due to chronic obstructive pulmonary disorder as a negative control outcome was informed by 301	
clinical knowledge of there being no direct relationship with the exposure  except through the 302	
possible confounder, smoking. Given a plausible negative control outcome or exposure, the method 303	
offers at least a means of testing for confounding, and potentially a method of adjustment under the 304	
assumption that the association between the unmeasured confounder and the negative outcome is 305	
similar in magnitude to that between the same confounder and the outcome of interest. 306	
 307	
3.2.4 Quasi-experimental adjustment assuming time-invariant longitudinal information 308	
 309	
We found 36 IVA studies that used lagged information or history about the individuals’ exposure 310	
as instruments 54,57–92. One study had recourse to the random assignment from a previous study, and 311	
used this as an instrument 69. Except for that and four other different exceptions, the instruments 312	
were all based at least in part on the previous intervention, or history of interventions, of the 313	
clinician or healthcare facility. Characteristics of the clinician or facility may be chosen as 314	
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instruments as they are more likely to affect the treatment only. This avoids direct associations with 315	
the individual and their outcome, and so better enforces the exclusion restriction – the exclusion of 316	
the instrument’s association with the outcome except through the treatment under study. While no 317	
assumptions are made about the dependence of confounding on time, the strength of the instrument 318	
clearly rests on a significant association between previous treatment(s) and the current treatment 319	
under investigation. In this regard, if the strength of an instrument varies with time, this may 320	
undermine its utility. 321	
 322	
In total, 24 studies also incorporated longitudinal information through the stable of methods that, in 323	
an abuse of terminology, we collectively referred to as the DiD approach. These included the 18 324	
examples cited as using DiD regression 93–110 alone, and four fixed effects (FE) 111–114. Either 325	
through fixed effects at the individual level or through aggregate-level regression operationalizing 326	
the DiD approach, these methods “ignore” the effect of confounding, which is assumed to be time-327	
invariant. At the individual level, time invariant confounding can be ignored by assigning nuisance 328	
dummy variables for each individual, or cancelled out through demeaning the observations, or 329	
through the first differences of observations on each individual. Two of the studies also extended 330	
DiD to allow different exposure effects and trends across two-level sub-groups in the higher-order 331	
contrast of difference-in-difference-in-differences 95,106. Fourteen studies also adjusted for 332	
individual-level fixed effects either through direct inclusion of their covariates, or through 333	
matching or weighting on the propensity score of the covariates. This was perhaps a more rigorous 334	
and precise approach, accounting for known confounders, and yielding smaller standard errors for 335	
the estimated treatment effect. However, an assumption of time-invariant confounding was still 336	
required, with a null difference between exposure groups in the prior period being evidence of 337	
adjustment for time-invariant confounding only. Two of the 24 DiD studies also re-analysed their 338	
data using IVA 38,47, which provided an albeit limited opportunity to compare the relative 339	
performance of these methods. In the study by Schmittdiel et al.  of how statins delivered by mail 340	
order affects cholesterol control47, the intervention coefficient from modelling the single main 341	
outcome was larger through DiD analysis and its standard error smaller than those from IVA, large 342	
standard errors being a feature of weak instruments. The study by Lei and Lin investigated the 343	
effect of exposure to a new medical scheme on 15 health outcomes and rates of health-service 344	
utilisation38. The effects were either not significantly different from the null or were significant and 345	
of similar magnitude with similar standard error except for two outcomes, where the effect size was 346	
significantly larger for IVA. 347	
 348	
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Time-invariant confounding, also known as the parallel trends assumption, was relaxed by 349	
including dummy variables for the year and its interaction with the treatment dummy in a fixed-350	
effects analysis, which allowed the unobserved trend to vary between exposure groups 113 using 351	
methods developed in economics and therefore not captured by this review 115,116. The results from 352	
this DiD with differential trend model were presented alongside those from the simple pooled DiD 353	
model and DiD with individual fixed-effects for the effect of financial incentives in care services. 354	
Tests confirmed parallel trends could be assumed in three outcomes, but out of the five outcomes 355	
presented, four were statistically significant and in all, the estimated effect size by differential 356	
trends was greater. 357	
 358	
Our review also included six studies applying the prior event rate ratio method, a before-and-after 359	
analogue applicable to survival and rate data 117–122. The first two published were the seminal 360	
presentation of the method applied to registry data. Also included was a comprehensive evaluation 361	
by Uddin et al. of the performance of PERR under a wide array of simulated, theoretical settings, 362	
under which bias was shown to increase with a greater effect of the prior events on subsequent 363	
exposure or intervention.  When prior events strongly influence the likelihood of treatment, the 364	
exposure effect from the PERR method can be more biased than estimates from conventional 365	
methods121. The problem was re-examined in a recently published study, which provided a more 366	
general statistical framework for PERR adjustment and considered the potential for generalising the 367	
method to allow more flexible modelling122.  368	
 369	
3.2.5 Dynamic, longitudinal quasi-experimental methods and time-varying information 370	
 371	
While regression discontinuity (RD) could suggest a longitudinal design, this is not exclusively so, 372	
and two RD studies were excluded because of this (one applied to spatial data while the other data 373	
was not longitudinal). Of those included all three could be said to accommodate time varying 374	
trends 123–125, and two of these were nested within a pre-post design: Zuckerman et al. were explicit 375	
in their methodological study in identifying the robustness to time-varying confounding, in which 376	
inhaler use in asthmatic patients was served as both the outcome variable in the post-test period as 377	
well as the assignment variable in the pre-test period125. In the study of the effect school-leaving 378	
age on mortality by Albouy, different slopes were modelled for the assignment variable, year of 379	
birth, after the cut-off date123. This acknowledged different maturation rates after assignment. 380	
However, as long as the assumptions of the method were met, assignment should have been as 381	
good as randomised, and so no further assumptions about the temporality of confounding was 382	
required. 383	
	 14
 384	
We also picked up six examples where IVA had been combined with either DiD or a fixed effects 385	
model, first appearing in our review with example from 2003 126. In Fortney’s 2005 study of 386	
treatment for depression 127, this combination method was justified as a control for time varying 387	
confounding, referred to as second-order endogeneity. Further examples of the fixed-effects 388	
instrumental variable model were found 128,129. The roles of lagged treatments and outcomes as 389	
possible IVs and predictors were extensively considered in O’Malley’s study of whether the 390	
introduction of more expensive medication could have led to improved cost-effectiveness in the 391	
long term54. The author cautioned that the exclusion restriction may be difficult to satisfy when 392	
using the lagged treatment as an IV after first differencing. However, two studies 130,131 used 393	
differences in the lagged explanatory variable as the IVs to adjust for second-order endogeneity in a 394	
first-differences analysis following methods, not captured by our review, but developed in the 395	
realm of Economics 132–134. Referred to as the dynamic panel model or IV-GMM, this method was 396	
implemented efficiently through generalised method of moments. In their report on healthcare 397	
expenditure in patients with rheumatoid arthritis, Kawatkar et al. found the yielded estimates were 398	
further from the null with larger standard errors when compared to those from FE alone130. 399	
 400	
3.3 Implementation of methods 401	
 402	
While choice of method in each study often rested on which extra information was available to 403	
address the issue of unmeasured confounding, method selection may also have been informed by 404	
the research area. The negative control method had its origins in epidemiology, with applications to 405	
occupational health policy. Likewise, the PERR method was developed exclusively on health data, 406	
with applications to drug safety and public health policy. Reflecting their origins in health 407	
econometrics, some studies were published in journals partially or entirely dedicated to the subject, 408	
with 15 published38,54,93–95,98,103,104,111–114,126,127,130 in this field out of the 32 studies using DiD and 409	
2923,24,28–30,32,33,36,41,46,48,49,51,52,66,69–72,77,81,84,86,135 out of the 86 using IVA. Under the inclusion 410	
criteria, all studies had health outcomes or interventions. Mendelian IVA necessarily includes 411	
genetic information, and all were published in health-related journals. In contrast, all three studies 412	
using RD were published in health econometric journals. 413	
 414	
Before implementing one of the proposed methods, a natural first step is for the researcher to try to 415	
assess how much bias from unmeasured confounding is likely to be present.  While many of the 416	
included studies reported raw or unadjusted descriptive estimates, bias estimation was limited 417	
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either to considering the contribution from known confounders, including those summarised as a 418	
propensity score, or to methods, such as perturbation testing/analysis and negative controls 419	
methods, in which bias evaluation is an incremental step in adjustment. Under the assumption of 420	
time-invariant confounding, the difference-in-differences method may potentially offer a way of 421	
evaluating bias by modelling group differences in the pre-exposure period. However, few studies 422	
evaluated hidden bias in this way47,96,112. The regression formulation of the DiD method effectively 423	
by-passes separate analysis of the prior period. Instead studies often discussed the within-group 424	
changes over time. Similarly, the prior-period estimate from the PERR method implicitly offers an 425	
evaluation of confounding bias under the same assumptions, yet none of the studies presented 426	
information on outcomes in the prior period in this way. A direct evaluation of unmeasured 427	
confounding is less straight-forward in IVA, with further diagnostic tests only recently developed 428	
for the association between instrument and confounders136,137 . 429	
	430	
4 Discussion 431	
 432	
This review examined the application of methods to detect and adjust for unmeasured confounding 433	
in observational studies, and was motivated by recent calls to utilise EHRs. Most of the reviewed 434	
studies used more established methods such as DiD and particularly IVA. We summarised how 435	
studies exploit the longitudinal information afforded by EHRs. 436	
 437	
It may be tempting to view electronic health records and medical insurance claims data as a 438	
problem of large observational data, and hence search for solutions through data mining. However, 439	
ethics governing patient data collection, plus limited clinician time is likely to preclude data with 440	
very large dimensions. For that reason, it is doubtful there would be enough dimensions for a 441	
method like Perturbation Analysis (PA) to be a practical solution. In addition, a greater number of 442	
variables would likely include enough information about the confounders to obviate the need for 443	
further adjustment through PA. More generally, the purpose of EHRs primarily as an administrative 444	
tool limits the scope for data mining of known confounders. Similarly, limited availability of gold-445	
standard datasets may have confined the use of external data, as in PSC, to but a few examples. 446	
 447	
We were surprised by the number of studies using IVA alone. While Mendelian randomisation has 448	
its advantages for many studies as a reasonable guarantor of the exclusion restriction, in general 449	
IVA typically suffers from the weak-instrument problem, resulting in large standard errors and 450	
wide confidence intervals. Longitudinal data offer an opportunity to reinforce the exclusion criteria 451	
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by choosing historical or lagged instruments. However in doing so, the causal structure needs to be 452	
understood to avoid opening up “back door” paths and inducing further bias54. DiD arguably offers 453	
advantages over IVA in being more intuitive and easier to conceptualise, and with the longitudinal 454	
data in EHRs it should be inherently easier to work with prior observations than to identify strong 455	
instruments. Even though before-and-after methods are not subject to the imprecision of weak 456	
instruments, the resulting estimates are only unbiased if the unobserved confounders exert a 457	
constant effect over the observation windows before and after exposure. Where multiple 458	
observations per individual exist, time may be paramaterised and different trends between exposure 459	
groups can be accommodated in DiD with differential trends, but a time invariant assumption about 460	
confounding must still be made. To partially or wholly relax this particular assumption, instrument 461	
variable analysis can be incorporated into the fixed effects model. Assuming the instrument’s 462	
exclusion restriction is satisfied then this doubly-robust approach affords the advantage of DiD 463	
over possibly weak instruments, while mitigating for some or all of the time-dependent 464	
confounders ignored by DiD alone. Similarly, where multiple previous treatments or exposures are 465	
recorded, the differenced lagged treatments can be utilised as IVs in a fixed effects model to 466	
accommodate time-dependent confounding bias using the generalized method of moments system, 467	
referred to as IV-GMM or the dynamic panel model. 468	
 469	
Another potentially robust approach to unmeasured confounding would the RD design, although 470	
the small number of examples in our review probably reflects the limited number of scenarios 471	
where this can be reasonably applied. Another concern over and above the usual technical 472	
challenges of applying the RD method is that in spite of heath records promising ample data, the 473	
sample would need to be reduced to an interval around the cut-off that ensures exchangeability of 474	
the two treatment groups. In this case generalisability would be restricted to individuals with 475	
characteristics found in the interval. As with RD, PERR was another method that was found in 476	
relatively few studies. This may have been in large part due to its recent development, rather than 477	
any technically demanding aspect of its application, since it simply extends the before-and-after 478	
approach of DiD to survival and rate data - outcomes that are common enough in health research.  479	
However, the PERR approach does require strong assumptions including time-invariant 480	
confounding and the absence of an effect of prior events on likelihood of future treatment122.   481	
 482	
Methods such as IVA and DiD have their origins in the sphere of econometrics, where randomised 483	
experiments are rare. We found that in importing DiD, some of the studies failed to explicitly 484	
acknowledge the problem of confounding bias. Instead justification for the method was presented 485	
in terms of the common trends assumption. Discussion of possible confounding bias is regarded as 486	
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essential by most QA toolkits for observational data, and it is important that health researchers 487	
explicitly recognise this threat to the internal validity of non-randomised studies. Conceptually a 488	
non-temporal analogue of DiD would be the NCO method, which itself was presented foremost as 489	
a method for detecting unmeasured confounding. Given doubts over satisfying necessary 490	
assumptions for their implementation, authors of this method along with propensity score 491	
calibration and perturbation analysis have suggested that, as sensitivity analyses, these can at least 492	
offer an insightful complement to QE adjustment.	 493	
 494	
Choosing between methods to reduce unmeasured confounding bias is challenging and we found 495	
few studies that directly compare methods. The performance of different methods will depend on 496	
factors such as the nature of the underlying confounding, the type of exposure and outcome, and 497	
the sample size138  The type of data available will also guide the choice of method.  For example, 498	
the instrumental variable method requires a suitable instrument and DiD / PERR require data on at 499	
least two periods. In practice, no one method is likely to be best suited to all problems, and it is 500	
essential for investigators to carefully assess the potential biases in each proposed study, where 501	
possible tailoring the methods or combination of methods to address these biases139.  Our review 502	
has highlighted how use of longitudinal information is one additional and potentially important 503	
consideration in this process.    504	
 505	
While our review focussed on the problem of adjustment using analytic methods, many problems 506	
associated with observational data may be pre-empted by use of an appropriate study design140.  507	
Before choosing an appropriate analytic method, it is recommended that investigators carefully 508	
identify and match individuals for the control and intervention groups in order not to exacerbate 509	
any bias3. The importance of study design is often discussed with a view to minimising 510	
confounding bias from unmeasured sources, with the subsequent adjustment accounting for 511	
observed confounders only141, usually through the matching, weighting or adjustment of propensity 512	
scores142. Where the success of the design remains in doubt, or its criteria cannot be fully met, then 513	
investigators will inevitably need recourse to some of the alternative methods reviewed in this 514	
report.  515	
 516	
The reviewed studies did not seek to distinguish between the different mechanisms of bias. 517	
Confounding by indication, deemed intractable by many researchers using the observed data143,  518	
was seen to create additional sources of bias in two separate simulation studies applying the 519	
“longitudinal” method of PERR, when an association was modelled between prior events and 520	
treatment status in the study period121,122. Another common form of selection bias in 521	
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pharmacoepidemiologic studies is the healthy user bias and this works in the opposite direction to 522	
confounding by indication, distorting treatment-outcome associations towards the treatment 523	
looking beneficial3.  Further research is needed to understand how each of the methods in this 524	
review is affected by the different types of confounding. 525	
 526	
An inherent limitation of this large, wide-ranging review is that it precluded meaningful data 527	
synthesis due to the mix of different data and study types.  Furthermore, we could only find a few 528	
examples where the performance of different methods was compared within the same study. We 529	
also stipulated in the inclusion criteria that unmeasured confounding, or any of its synonyms, 530	
should be given as justification for methods in its adjustment. This may have inadvertently 531	
excluded some papers, where justification was implicit, but good practice in health research 532	
demands acknowledgement of this source of bias where applicable. While our search terms were 533	
specific to the scope of our review, we accept that this may have inadvertently excluded relevant 534	
methods and studies. Some methods, such as negative control outcomes, that were identified in the 535	
original search were not included as explicit terms in the search strategy, and further secondary 536	
searches may have uncovered additional studies using these methods. We also acknowledge that 537	
there may be other relevant methods for addressing unmeasured confounding that have been missed 538	
by the search strategy. Consequently, we made inferences about the relative application of methods 539	
with caution. However, we were surprised so many studies focussed solely on IVA as the sole 540	
means of adjustment. A similar conclusion was echoed by a different review on regression 541	
discontinuity designs that found interest was growing in RD only as recently as 2014 144. 542	
 543	
By choosing to focus on methods with an independent control arm for each treatment, our review 544	
excluded case only designs including case-crossover designs (CCO) and the self-controlled case-545	
series design.  This class of methods addresses unmeasured confounding by making comparisons 546	
within individuals so that each individual acts as his or her own control.  Another case-only design, 547	
the case-time control design, is an extension of the CCO design that uses information from a 548	
historical control group in a similar way to the PERR method.  These approaches are reviewed by 549	
Uddin et al138 and Nordmann et al145. 550	
 551	
This review has considered a range of promising new methods for addressing unmeasured 552	
confounding in non-randomised studies. However, consistent with prior research on dissemination 553	
and uptake of statistical innovations146, the rate of knowledge translation has been slow and we 554	
found that most studies in our review used established methods such as IVA and DiD.  A recent 555	
study by Cadarette et al has shown how Rogers’ Diffusion of Innovations model can be used to 556	
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describe the adoption of novel methodologies in pharmacoepidemiology147 and this provides a 557	
useful resource for interpreting the uptake of methods in this review.  Cadarette et al proposed five 558	
principles for authors of methodological innovations that may improve translation into practice 147: 559	
(1) clearly describing the methods using foundational principles; (2) comparing results to 560	
established methods; (3) providing sample data, code or calculation examples; (4) early 561	
communication, support and testing; and (5) providing methodological and reporting guidance. 562	
These recommendations offer a useful checklist for researchers developing methods for addressing 563	
unmeasured confounding in observational studies. Of particular relevance in the context of this 564	
review is the need for more extensive evaluation and comparison of the emerging methods in a 565	
range of settings.   The review also addresses the need for methodological guidance through 566	
highlighting the potentially important role of longitudinal information in addressing confounding 567	
bias and has identified this as an area for further development. 568	
5 Conclusions 569	
	570	
Our review showed how seminal work in econometrics has influenced practice in dealing with 571	
unmeasured confounding in clinical and epidemiological research. Although the issue of 572	
unmeasured confounding is widely acknowledged, we found that longitudinal information in 573	
observational studies appears under-utilised. Lagged and historical characteristics associated with 574	
the treatment may help enforce the exclusion restrictions of instrumental variables under the 575	
appropriate causal structures, while before-and-after methods, such as DiD and PERR, afford an 576	
intuitive approach without the imprecision of weak instruments. Furthermore, they offer a direct 577	
evaluation of time-invariant confounding bias. The most robust methods we found applied 578	
instrumental variable analysis to the fixed effects difference-in-differences method, where such 579	
suitable instruments or difference lagged variables could be assumed to satisfy the exclusion 580	
restriction.  While there are sometimes good technical reasons for choosing one mode of analysis 581	
over another, many questions remain over the most appropriate methods.  All methods rely on 582	
assumptions, but little guidance is available to applied researchers as to the empirical settings in 583	
which particular methods can be safely used.  Few studies directly compare different methods and 584	
more research is needed to the establish the relative performance of the methods in realistic 585	
settings.   586	
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Figure	2:	Plot	of	frequency	of	reviewed	methods	for	mitigating	for	unmeasured	confounding	by:	difference‐in‐differences	[black];	Instrumental	variable	analysis	(IVA)	[mid‐grey];	
Other	[light	grey]	includes	regression	discontinuity,	prior	event	rate	ratio	method,	propensity	score	calibration,	perturbation	analysis,	negative	control	outcomes,	fixed	effects	with	
IVA	and	dynamic	panel	models.	Note:	the	low	frequencies	in	2015	was	attributable	to	the	May	cut‐off	for	inclusion	in	that	year.
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Method  Description  Obstacles to implementation  Frequency of methods 
Instrumental variable 
analysis (IVA) 
Upon identification of a suitably strong instrument, the influence of bias may be reduced 
through post‐hoc randomisation. The instrumental variable should be highly determinant of 
the intervention or treatment received, while satisfying the exclusion assumption of being 
independent of the outcome other than through the treatment (Wright 1928; Angrist 1991). 
In practice, finding an instrument with a sufficiently strong treatment association is a stumbling 
block in many analyses (Bound, Jaeger, and Baker 1995; Baser 2009). Association of the instrument 
with the outcome exclusively through the treatment is an untestable assumption, particularly if an 
indirect association exists through an unmeasured covariate. 
79 
Difference‐in‐
differences (DiD) 
A biased effect estimate between two treatment groups may be corrected by the same 
estimates from a treatment‐free period prior to the exposure, which should be a measure of 
the confounding bias contributed to the treatment effect (Ashenfelter and Card 1984). 
Aggregated at the treatment group level, this is operationalised in regression as a period‐
treatment interaction. At an individual level, demeaning, first‐differencing or dummy 
variables for each individual may yield bias‐free fixed effects, contingent on assumptions. 
The method is contingent on the availability of repeated outcomes in both periods and  invokes a 
time‐invariant confounding assumption: that the confounding bias as captured by the estimated 
treatment effect in a treatment‐free period prior to exposure is constant through to the study 
period. 
24 
Prior event rate ratio 
(PERR) 
Analogous to the DiD method for time‐to‐event or rate data, a biased estimate of the hazard 
ratio or the incidence rate ratio is adjusted through its ratio with that from a treatment‐free 
prior period (Tannen et al. 2008). 
As with the assumption for DiD, repeatable outcomes and a constancy of the unmeasured 
confounding bias is required across both periods, before and after the exposure.  Prior event 
occurrence should not influence the likelihood of future treatment. 
5 
Fixed effects 
instrumental variable 
analysis (FE IVA) 
IVA may be applied to DiD estimation to mitigate for second‐order endogeneity: the time‐
varying part of the bias that may not have been adjusted for by DiD.  Assumptions of IVA apply  5 
Dynamic panel model, 
or Instrumental variable 
‐ generalised method of 
moments (IV‐GMM) 
Lagged observations of the confounded (endogenous) explanatory variable are introduced in 
a first‐differences fixed effects analysis so that the differences of the lags become the 
instrumental variables in a generalised method of moments estimation. 
Assumptions of IVA apply. Here the differenced lags should not be correlated with the differences 
in the error terms.  2 
Regression 
discontinuity (RD) 
RD is a design for analysis based on a treatment assignment determined by a cut‐off applied 
to a continuous variable that is preferably measured with some random noise (as many 
clinical tests may be). The outcome can then be modelled on treatment for individuals within 
a certain interval from the cut‐off of the assignment variable to ensure exchangeability 
between individuals for robust causal inference (Thistlethwaite and Campbell 1960) 
Where assignment is not sharply determined by the cut‐off, an increase in the probability of 
treatment may be observed leading to a "fuzzy" version of RD. Continuity in the assignment 
variable is assumed, otherwise manipulation of assignment and reverse causality may be 
suspected. Assignment should be locally random around the cut‐off and makes the weak 
assumption that no unobserved covariates are  discontinuous around the assignment cut‐off. 
3 
Propensity score 
calibration (PSC) 
PSC adjusts for residual confounding in the error‐prone main dataset by importing 
information about the unmeasured confounders from a smaller, external “gold‐standard” 
dataset (Stürmer et al. 2005). Analysis in the main dataset is adjusted using a single 
dimension propensity score of the measured corrected for unmeasured confounding by 
regression calibration against the gold‐standard propensity score. 
Successful adjustment is wholly dependent on the availability of another dataset containing the 
exposure variable and error‐free predictor,  with individuals that are relevant enough to those in 
the main dataset and under similar enough conditions to assure sufficient overlap between the 
two datasets. 
3 
Perturbation 
testing/analysis (PT/PA) 
This data mining approach aims to mitigate for unmeasured confounding by adjusting for 
many measured variables that are weakly associated with the unobserved confounding 
variables (Lee 2014). Simulation in the single reviewed example demonstrated this may 
require 100's, if not 1000's of perturbation variables (PV). 
This requires a very highly dimensional dataset, which may ultimately obviate the need for indirect 
adjustment if the most or all of the confounders are captured. Simulation demonstrated the bias 
may be exaggerated if a confounder is inadvertently identified as a PV, requiring many more true 
PVs to correct the bias. The number of PVs may exceed the available degrees of freedom 
necessitating clustering. 
1 
Negative control 
outcome / exposure 
(NCO/NCE) 
A negative controlis causally related to measured and unmeasured confounders affecting the 
exposure and main outcome, but not directly causally related to exposure and outcome 
themselves. As such, the negative control may be used to detect confounding bias in the 
main study, and potentially to indirectly adjust for this (Richardson et al. 2014) 
This assumes that the effect of the unmeasured confounders on the main outcome is similar to 
that affecting the negative control.  1 
Table	1:	Summary	of	methods	to	mitigate	against	unmeasured	confounding	captured	by	systematic	review,	and	the	frequency	of	their	use	amongst	the	captured	papers	
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IV type  Explanation/ Example  No. of papers  Total frequency
Mendelian  Genetic characteristics :Single 
nucleotide polymorphisms 
11  11 
Geographic 
Differential distance between 
patient's postcode and nearest 
health facility 
19 
1 
 
1 
20 
Time  Time‐based characteristic of 
treatment such as date of therapy 
6 
2 
10 
Historical 
Usually prescribing preference of 
physician or facility based on 
historical records of previously 
administered therapies 
31     34 
Lagged  Previous therapy or outcome of 
patient 
6  6 
Randomisation  Original randomisation  1  1 
Other 
Characteristics of individual 
e.g: age of patient, weight of 
offspring 
8  8 
Table	2:	Frequency	of	instruments	categorised	by	type	used	in	instrumental	variable	analyses	
	 	
	 28
Appendix A 
	
1. ("prior event" and ratio).ti,ab. 
 
2. "paired cox model".ti,ab. 
 
3. 1 or 2 
 
4. instrumental variables.ti,ab. 
 
5. instrumental variable analysis/ 
 
6. propensity score calibration.ti,ab. 
 
7. regression discontinuity design.ti,ab. 
 
8. "difference in differences".ti,ab. 
 
9. (difference adj1 differences).ti,ab. 
 
10. "ratio of ratios".ti,ab. 
 
11. (ratio adj1 ratios).ti,ab. 
 
12. interrupted time series.ti,ab. 
 
13. segmented regression.ti,ab. 
 
14. (sensitivity analysis/ or sensitivity analysis.ti,ab.) and ((unmeasured or residual or hidden) and 
(confounding or confounder*)).ti,ab. 
 
15. or/4-14 
 
16. ((unmeasured or residual or hidden or unobserved or omitted) and (confounding or 
confounder*)).ti,ab. 
 
17. confounding variable/ 
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18. covariates.ti,ab. 
 
19. bias.ti,ab. 
 
20. selection bias/ 
 
21. 16 or 17 or 18 or 19 or 20 
 
22. observational study/ 
 
23. (observation* adj (stud* or data)).ti,ab. 
 
24. ((before adj after) and (study or studies)).ti,ab. 
 
25. (nonrandomi?ed or non randomi?ed).ti,ab. 
 
26. case crossover.ti,ab. 
 
27. case control.ti,ab. 
 
28. case control study/ 
 
29. cohort study.ti,ab. 
 
30. (quasi experiment* or quasiexperiment*).ti,ab. 
 
31. quasi-experimental study/ 
 
32. cross sectional study.ti,ab. 
 
33. cross-sectional study/ 
 
34. simulation.ti,ab. 
 
35. case time control.ti,ab. 
	 30
 
36. ("before and after" and (study or studies)).ti,ab. 
 
37. or/22-36 
 
38. 16 and 19 and 37 
 
39. 3 or 15 
 
40. 39 and 37 and 21 
 
41. 38 or 40 
 
42. 21 or 37 
 
43. 39 and 42 
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Table	3:	Table	of	included	studies	denoting	QE	method	used	and	type	of	instrument,	if	applicable,	where:	IVA	=	instrumental	variable	analysis;	RD	=	regression	discontinuity;	DiD	=	
difference‐in‐differences;	DiDiD	=	difference‐in‐difference‐in‐differences;	PSC	=	propensity	score	calibration;	PERR	=	prior	event	rate	ratio	
Author	 Title	 Year	 QE	method	 If	IVA,	IV	type	
Bryson,	W.	C.;	McConnell,	J.;	
Krothuis,	T.;	McCarty,	D.	
Extended‐release	naltrexone	for	alcohol	
dependence:	persistence	and	healthcare	
costs	and	utilization	
2011	 DiD	
Cheng,	L.;	Liu,	H.;	Zhang,	Y.;	Shen,	
K.;	Zeng,	Y.	
The	impact	of	health	insurance	on	health	
outcomes	and	spending	of	the	elderly:	
Evidence	from	china's	new	cooperative	
medical	scheme	
2015	 DiD	
Gebel,	M.;	Vosemer,	J.	 The	impact	of	employment	transitions	on	
health	in	Germany.	A	difference‐in‐
differences	propensity	score	matching	
approach	
2014	 DiD	
Goetzel,	R.	Z.;	Roemer,	E.	C.;	Pei,	X.;	
Short,	M.	E.;	Tabrizi,	M.	J.;	Wilson,	M.	
G.;	Dejoy,	D.	M.;	Craun,	B.	A.;	Tully,	K.	
J.;	White,	J.	M.;	Baase,	C.	M.	
Second‐year	results	of	an	obesity	
prevention	program	at	the	dow	chemical	
company	
2010	 DiD	
Higgins,	S.;	Chawla,	R.;	Colombo,	
C.;	Snyder,	R.;	Nigam,	S.	
Medical	homes	and	cost	and	utilization	
among	high‐risk	patients	
2014	 DiD	
Kausto,	J.;	Viikari‐Juntura,	E.;	
Virta,	L.	J.;	Gould,	R.;	Koskinen,	A.;	
Solovieva,	S.	
Effectiveness	of	new	legislation	on	partial	
sickness	benefit	on	work	participation:	a	
quasi‐experiment	in	Finland	
2014	 DiD	
	 32	
Kelly,	Y.;	Kelly,	J.;	Sacker,	A.	 Changes	in	bedtime	schedules	and	
behavioral	difficulties	in	7	year	old	
children	
2013	 DiD	
Lin,	W.	C.;	Chien,	H.	L.;	Willis,	G.;	
O'Connell,	E.;	Rennie,	K.	S.;	Bottella,	
H.	M.;	Ferris,	T.	G.	
The	effect	of	a	telephone‐based	health	
coaching	disease	management	program	
on	medicaid	members	with	chronic	
conditions	
2012	 DiD	
Lyon,	S.	M.;	Wunsch,	H.;	Asch,	D.	A.;	
Carr,	B.	G.;	Kahn,	J.	M.;	Cooke,	C.	R.	
Use	of	intensive	care	services	and	
associated	hospital	mortality	after	
massachusetts	healthcare	reform	
2014	 DiD	
Menon,	J.;	Paulet,	M.;	Thomas,	Iii	J.	 Wellness	coaching	and	health‐related	
quality	of	life:	A	case‐control	difference‐
in‐differences	analysis	
2012	 DiD	
Moran,	J.	R.;	Short,	P.	F.;	Hollenbeak,	
C.	S.	
Long‐term	employment	effects	of	
surviving	cancer	
2011	 DiD	
Osborne,	N.	H.;	Nicholas,	L.	H.;	Ryan,	
A.	M.;	Thumma,	J.	R.;	Dimick,	J.	B.	
Association	of	hospital	participation	in	a	
quality	reporting	program	with	surgical	
outcomes	and	expenditures	for	medicare	
beneficiaries	
2015	 DiD	
Reid,	R.	O.;	Ashwood,	J.	S.;	Friedberg,	
M.	W.;	Weber,	E.	S.;	Setodji,	C.	M.;	
Mehrotra,	A.	
Retail	clinic	visits	and	receipt	of	primary	
care	
2013	 DiD	
	 33	
Sadhu,	A.	R.;	Ang,	A.	C.;	Ingram‐
Drake,	L.	A.;	Martinez,	D.	S.;	
Hsueh,	W.	A.;	Ettner,	S.	L.	
Economic	benefits	of	intensive	insulin	
therapy	in	critically	Ill	patients:	The	
targeted	insulin	therapy	to	improve	
hospital	outcomes	(TRIUMPH)	project	
2008	 DiD	
Sarkar,	U.;	Lyles,	C.	R.;	Parker,	M.	M.;	
Allen,	J.;	Nguyen,	R.;	Moffet,	H.	H.;	
Schillinger,	D.;	Karter,	A.	J.	
Use	of	the	refill	function	through	an	online	
patient	portal	is	associated	with	improved	
adherence	to	statins	in	an	integrated	
health	system	
2014	 DiD	
Watt,	C.;	Abuya,	T.;	Warren,	C.	E.;	
Obare,	F.;	Kanya,	L.;	Bellows,	B.	
Can	reproductive	health	voucher	
programs	improve	quality	of	postnatal	
care?	A	quasi‐experimental	evaluation	of	
Kenya	'	s	Safe	Motherhood	voucher	
scheme	
2015	 DiD	
De	Preux,	L.	B.	 Anticipatory	ex	ante	moral	hazard	and	the	
effect	of	medicare	on	prevention	
2011	 DiD;	DiDiD	
Rajaram,	R.;	Chung,	J.	W.;	Jones,	A.	T.;	
Cohen,	M.	E.;	Dahlke,	A.	R.;	Ko,	C.	Y.;	
Tarpley,	J.	L.;	Lewis,	F.	R.;	Hoyt,	D.	B.;	
Bilimoria,	K.	Y.	
Association	of	the	2011	ACGME	resident	
duty	hour	reform	with	general	surgery	
patient	outcomes	and	with	resident	
examination	performance	
2014	 DiD;	DiDiD	
Domino,	M.	E.;	Norton,	E.	C.;	
Morrissey,	J.	P.;	Thakur,	N.	
Cost	shifting	to	jails	after	a	change	to	
managed	mental	health	care	
2004	 DiD;	Fixed	effects	
Hodgkin,	D.;	Parks	Thomas,	C.;	
Simoni‐Wastila,	L.;	Ritter,	G.	A.;	Lee,	
S.	
The	effect	of	a	three‐tier	formulary	on	
antidepressant	utilization	and	
expenditures	
2008	 Fixed	effects	
	 34	
Li,	J.;	Hurley,	J.;	DeCicca,	P.;	
Buckley,	G.	
Physician	response	to	pay‐for‐
performance:	evidence	from	a	natural	
experiment	
2014	 DiD	pooled	OLS;	DiD	
(Fixed	effects);	DiD	+	
differential	trends	
Yoon,	J.;	Bernell,	S.	L.	 The	role	of	adverse	physical	health	events	
on	the	utilization	of	mental	health	services
2013	 DiD	&	Fixed	Effects	
Fortney,	J.	C.;	Steffick,	D.	E.;	Burgess	
Jr,	J.	F.;	Maciejewski,	M.	L.;	Petersen,	
L.	A.	
Are	primary	care	services	a	substitute	or	
complement	for	specialty	and	inpatient	
services?	
2005	 IVA	applied	to	DiD	 Geographic	
Hay,	J.;	Jhaveri,	M.;	Tangirala,	M.;	
Kaliner,	M.	
Cost	and	resource	utilization	comparisons	
of	second‐generation	antihistamines	vs.	
montelukast	for	allergic	rhinitis	treatment	
2009	 IVA	applied	to	Fixed	
effects	
Historical	
Chung,	S.;	Domino,	M.	E.;	Stearns,	S.	
C.	
The	effect	of	retirement	on	weight	 2009	 Fixed	Effects;	IVA	
applied	to	Fixed	effects	
Lagged	
Wagner,	T.	H.;	Jimison,	H.	B.	 Computerized	health	information	and	the	
demand	for	medical	care	
2003	 IVA	applied	to	Fixed	
effects	
Other	
Kawatkar,	A.	A.;	Hay,	J.	W.;	Stohl,	W.;	
Nichol,	M.	B.	
Incremental	expenditure	of	biologic	
disease	modifying	antirheumatic	
treatment	using	instrumental	variables	in	
panel	data	
2013	 Dynamic	panel	model	
(IV‐GMM)	
Lagged	
	 35	
Piernas,	C.;	Ng,	S.	W.;	Mendez,	M.	A.;	
Gordon‐Larsen,	P.;	Popkin,	B.	M.	
A	dynamic	panel	model	of	the	associations	
of	sweetened	beverage	purchases	with	
dietary	quality	and	food‐purchasing	
patterns	
2015	 Dynamic	panel	model	
(IV‐GMM)	
Lagged	
Lei,	X.;	Lin,	W.	 The	new	cooperative	medical	scheme	in	
rural	China:	Does	more	coverage	mean	
more	service	and	better	health?	
2009	 Fixed	effects;	IVA;	DiD	 Geographic	
Lin,	M.	J.;	Liu,	J.	T.	 Do	lower	birth	weight	babies	have	lower	
grades?	Twin	fixed	effect	and	
instrumental	variable	method	evidence	
from	Taiwan	
2009	 Fixed	effects;	IVA	 Geographic	
Schmittdiel,	J.	A.;	Karter,	A.	J.;	
Dyer,	W.;	Parker,	M.;	Uratsu,	C.;	
Chan,	J.;	Duru,	O.	K.	
The	comparative	effectiveness	of	mail	
order	pharmacy	use	vs.	local	pharmacy	
use	on	LDL‐C	control	in	new	statin	users	
2011	 DiD;	IVA	 Other	
Basu,	A.	 Estimating	Decision‐Relevant	
Comparative	Effects	Using	Instrumental	
Variables	
2011	 IVA	 Geographic	
Beck,	C.	A.;	Penrod,	J.;	Gyorkos,	T.	
W.;	Shapiro,	S.;	Pilote,	L.	
Does	Aggressive	Care	Following	Acute	
Myocardial	Infarction	Reduce	Mortality?	
Analysis	with	Instrumental	Variables	to	
Compare	Effectiveness	in	Canadian	and	
United	States	Patient	Populations	
2003	 IVA	 Geographic	
Chen,	L.	F.;	Chen,	H.	P.;	Huang,	Y.	S.;	
Huang,	K.	Y.;	Chou,	P.;	Lee,	C.	C.	
Pneumococcal	Pneumonia	and	the	Risk	of	
Stroke:	A	Population‐Based	Follow‐Up	
Study	
2012	 IVA	 Geographic	
	 36	
Edwards,	S.	T.;	Prentice,	J.	C.;	Simon,	
S.	R.;	Pizer,	S.	D.	
Home‐Based	Primary	Care	and	the	risk	of	
ambulatory	care‐sensitive	condition	
hospitalization	among	older	veterans	with	
diabetes	mellitus	
2014	 IVA	 Geographic	
Frances,	C.	D.;	Shlipak,	M.	G.;	
Noguchi,	H.;	Heidenreich,	P.	A.;	
McClellan,	M.	
Does	physician	specialty	affect	the	
survival	of	elderly	patients	with	
myocardial	infarction?	
2000	 IVA	 Geographic	
Goldman,	D.	P.;	Bao,	Y.	 Effective	HIV	treatment	and	the	
employment	of	HIV+	adults	
2004	 IVA	 Geographic	
Gowrisankaran,	G.;	Town,	R.	J.	 Estimating	the	quality	of	care	in	hospitals	
using	instrumental	variables	
1999	 IVA	 Geographic	
Hirth,	R.	A.;	Grabowski,	D.	C.;	Feng,	
Z.;	Rahman,	M.;	Mor,	V.	
Effect	of	nursing	home	ownership	on	
hospitalization	of	long‐stay	residents:	An	
instrumental	variables	approach	
2014	 IVA	 Geographic	
Kahn,	J.	M.;	Werner,	R.	M.;	David,	
G.;	Ten	Have,	T.	R.;	Benson,	N.	M.;	
Asch,	D.	A.	
Effectiveness	of	long‐term	acute	care	
hospitalization	in	elderly	patients	with	
chronic	critical	illness	
2013	 IVA	 Geographic	
Linden,	A.;	Adams,	J.	L.	 Evaluating	disease	management	
programme	effectiveness:	An	introduction	
to	instrumental	variables	
2006	 IVA	 Geographic	
	 37	
Norton,	E.	C.;	Lindrooth,	R.	C.;	
Ennett,	S.	T.	
Controlling	for	the	endogeneity	of	peer	
substance	use	on	adolescent	alcohol	and	
tobacco	use	
1998	 IVA	 Geographic	
Pilote,	L.;	Beck,	C.	A.;	Eisenberg,	M.	J.;	
Humphries,	K.;	Joseph,	L.;	Penrod,	J.	
R.;	Tu,	J.	V.	
Comparing	invasive	and	noninvasive	
management	strategies	for	acute	
myocardial	infarction	using	
administrative	databases	
2008	 IVA	 Geographic	
Pracht,	E.	E.;	Tepas,	Iii	J.	J.;	Celso,	B.	
G.;	Langland‐Orban,	B.;	Flint,	L.	
Survival	advantage	associated	with	
treatment	of	injury	at	designated	trauma	
centers:	A	bivariate	probit	model	with	
instrumental	variables	
2007	 IVA	 Geographic	
Slade,	E.	P.;	McCarthy,	J.	F.;	
Valenstein,	M.;	Visnic,	S.;	Dixon,	L.	B.	
Cost	savings	from	assertive	community	
treatment	services	in	an	era	of	declining	
psychiatric	inpatient	use	
2013	 IVA	 Geographic	
Tsai,	A.	C.;	Votruba,	M.;	Bridges,	J.	F.	
P.;	Cebul,	R.	D.	
Overcoming	bias	in	estimating	the	
volume‐outcome	relationship	
2006	 IVA	 Geographic	
Wehby,	G.	L.;	Ullrich,	F.;	Xie,	Y.	 Very	low	birth	weight	hospital	volume	
and	mortality:	An	instrumental	variables	
approach	
2012	 IVA	 Geographic	
Hadley,	J.;	Polsky,	D.;	Mandelblatt,	J.	
S.;	Mitchell,	J.	M.;	Weeks,	J.	C.;	Wang,	
Q.;	Hwang,	Y.	T.	
An	exploratory	instrumental	variable	
analysis	of	the	outcomes	of	localized	
breast	cancer	treatments	in	a	medicare	
population	
2003	 IVA	 Geographic	+	
Historical	+	
Time	
	 38	
O'Malley,	A.	J.;	Frank,	R.	G.;	
Normand,	S.	L.	T.	
Estimating	cost‐offsets	of	new	
medications:	Use	of	new	antipsychotics	
and	mental	health	costs	for	schizophrenia	
2011	 IVA	 Geographic	+	
Time	
Abrahamowicz,	M.;	Beauchamp,	M.	
E.;	Ionescu‐Ittu,	R.;	Delaney,	J.	A.	C.;	
Pilote,	L.	
Reducing	the	variance	of	the	prescribing	
preference‐based	instrumental	variable	
estimates	of	the	treatment	effect	
2011	 IVA	 Historical	
An,	J.;	Nichol,	M.	B.	 Multiple	medication	adherence	and	its	
effect	on	clinical	outcomes	among	patients	
with	comorbid	type	2	diabetes	and	
hypertension	
2013	 IVA	 Historical	
Bekelman,	J.	E.;	Mitra,	N.;	Handorf,	E.	
A.;	Uzzo,	R.	G.;	Hahn,	S.	A.;	Polsky,	D.;	
Armstrong,	K.	
Effectiveness	of	androgen‐deprivation	
therapy	and	radiotherapy	for	older	men	
with	locally	advanced	prostate	cancer	
2015	 IVA	 Historical	
Bhowmik,	D.;	Aparasu,	R.	R.;	Rajan,	
S.	S.;	Sherer,	J.	T.;	Ochoa‐Perez,	M.;	
Chen,	H.	
Risk	of	manic	switch	associated	with	
antidepressant	therapy	in	pediatric	
bipolar	depression	
2014	 IVA	 Historical	
Brooks,	J.	M.;	Tang,	Y.;	Chapman,	C.	
G.;	Cook,	E.	A.;	Chrischilles,	E.	A.	
What	is	the	effect	of	area	size	when	using	
local	area	practice	style	as	an	instrument?	
2013	 IVA	 Historical	
Chuang,	C.	M.;	Chou,	Y.	J.;	Yen,	M.	S.;	
Chao,	K.	C.;	Twu,	N.	F.;	Wu,	H.	H.;	
Wen,	K.	C.;	Chen,	Y.	J.;	Wang,	P.	H.;	
Lai,	C.	R.;	Chou,	P.	
The	role	of	secondary	cytoreductive	
surgery	in	patients	with	recurrent	
epithelial	ovarian,	tubal,	and	peritoneal	
cancers:	A	comparative	effectiveness	
analysis	
2012	 IVA	 Historical	
	 39	
De	Ridder,	A.;	De	Graeve,	D.	 Can	we	account	for	selection	bias?	A	
comparison	between	bare	metal	and	drug‐
eluting	stents	
2011	 IVA	 Historical	
Fang,	G.;	Brooks,	J.	M.;	Chrischilles,	
E.	A.	
Comparison	of	instrumental	variable	
analysis	using	a	new	instrument	with	risk	
adjustment	methods	to	reduce	
confounding	by	indication	
2012	 IVA	 Historical	
Figueroa,	R.;	Harman,	J.;	Engberg,	J.	 Use	of	Claims	Data	to	Examine	the	Impact	
of	Length	of	Inpatient	Psychiatric	Stay	on	
Readmission	Rate	
2004	 IVA	 Historical	
Huesch,	M.	D.	 External	adjustment	sensitivity	analysis	
for	unmeasured	confounding:	An	
application	to	coronary	stent	outcomes,	
Pennsylvania	2004‐2008	
2013	 IVA	 Historical	
Huybrechts,	K.	F.;	Brookhart,	M.	A.;	
Rothman,	K.	J.;	Silliman,	R.	A.;	
Gerhard,	T.;	Crystal,	S.;	Schneeweiss,	
S.	
Comparison	of	different	approaches	to	
confounding	adjustment	in	a	study	on	the	
association	of	antipsychotic	medication	
with	mortality	in	older	nursing	home	
patients	
2011	 IVA	 Historical	
Ionescu‐Ittu,	R.	 Treatment	effect	estimates	varied	
depending	on	the	definition	of	the	
provider	prescribing	preference‐based	
instrumental	variables	
2012	 IVA	 Historical	
Kivimaki,	M.;	Vahtera,	J.;	Kawachi,	
I.;	Ferrie,	J.	E.;	Oksanen,	T.;	
Joensuu,	M.;	Pentti,	J.;	Salo,	P.;	
Elovainio,	M.;	Virtanen,	M.	
Psychosocial	work	environment	as	a	risk	
factor	for	absence	with	a	psychiatric	
diagnosis:	An	instrumental‐variables	
analysis	
2010	 IVA	 Historical	
	 40	
Kramer,	A.;	Jager,	K.	J.;	Fogarty,	D.	G.;	
Ravani,	P.;	Finne,	P.;	Perez‐Panades,	
J.;	Prutz,	K.	G.;	Arias,	M.;	Heaf,	J.	G.;	
Wanner,	C.;	Stel,	V.	S.	
Association	between	pre‐transplant	
dialysis	modality	and	patient	and	graft	
survival	after	kidney	transplantation	
2012	 IVA	 Historical	
Kuo,	Y.	F.;	Montie,	J.	E.;	Shahinian,	
V.	B.	
Reducing	bias	in	the	assessment	of	
treatment	effectiveness:	Androgen	
deprivation	therapy	for	prostate	cancer	
2012	 IVA	 Historical	
Lakdawalla,	D.	N.;	Mascarenhas,	
M.;	Jena,	A.	B.;	Vanderpuye‐Orgle,	
J.;	Lavallee,	C.;	Linthicum,	M.	T.;	
Snider,	J.	T.	
Impact	of	oral	nutrition	supplements	on	
hospital	outcomes	in	pediatric	patients	
2014	 IVA	 Historical	
MacKenzie,	T.	A.;	Tosteson,	T.	D.;	
Morden,	N.	E.;	Stukel,	T.	A.;	O'Malley,	
A.	J.	
Using	instrumental	variables	to	estimate	a	
Cox's	proportional	hazards	regression	
subject	to	additive	confounding	
2014	 IVA	 Historical	
Margolis,	D.	J.;	Gupta,	J.;	Hoffstad,	O.;	
Papdopoulos,	M.;	Glick,	H.	A.;	Thom,	
S.	R.;	Mitra,	N.	
Lack	of	effectiveness	of	hyperbaric	oxygen	
therapy	for	the	treatment	of	diabetic	foot	
ulcer	and	the	prevention	of	amputation	a	
cohort	study	
2013	 IVA	 Historical	
Parmar, A. D.; Sheffield, K. M.; Han, Y.; 
Vargas, G. M.; Guturu, P.; Kuo, Y. F.; 
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